FDA approves a tiny robot for surgery to remove bladder tumors

FDA approves a tiny robot for surgery to remove bladder tumors

FDA clears robotic system for removing bladder tumors

When a bladder tumor is removed, the tissue can help doctors determine whether it is cancer and how far it has grown. A newly authorized surgical robot is designed to help surgeons remove some tumors in one piece, potentially giving pathologists a more complete sample to examine.

The FDA granted De Novo authorization to the Virtuoso Endoscopy System, developed by Nashville-based Virtuoso Surgical. The device uses two tiny robotic arms to remove bladder lesions through the urethra, without an incision through the skin. Surgeons control the arms from a console; the system does not make decisions or operate on its own.

A rigid endoscope guides the instrument into the bladder. At its tip, two small arms made from a flexible metal alloy called nitinol work together: one lifts and holds the tumor while the other separates it from the surrounding tissue. The approach is intended to make en bloc resection—the removal of a tumor in one piece—easier to perform in the confined space.

Surgeons can already remove bladder tumors this way using conventional instruments, but the procedure can be technically challenging. In a common procedure known as transurethral resection of bladder tumor, or TURBT, tumors are often removed in fragments. That can disrupt the tissue’s structure and make it harder for pathologists to judge how deeply the cancer has grown.

In particular, doctors need to know whether cancer has reached the detrusor muscle, a layer of muscle in the bladder wall. That finding can affect treatment decisions. An intact sample may preserve more useful detail about the tumor and the tissue around it.

In the first 20 patients enrolled in the company-sponsored VIABLE study at The Chinese University of Hong Kong, 94% of removed lesions contained detrusor muscle. The study’s predefined performance goal was 60%. Researchers said they were able to evaluate surgical margins in 93% of malignant lesions. Margins are the edges of the removed tissue; examining them can help show whether cancer cells extend to the edge of the sample, though an evaluable margin is not necessarily cancer-free. The company reported no adverse events during those operations.

The findings are still preliminary. The study involved a small group of patients at a single medical center, and it did not directly compare the robot with conventional instruments in a randomized trial. A previously published first phase of the same study included six patients and recorded two postoperative adverse events: one case of temporary urinary retention and one chest infection later linked to a separate esophageal tumor. Researchers will need larger studies to determine whether the system improves long-term outcomes or reduces the need for further procedures.

The FDA granted the system De Novo authorization on October 30, 2026, and the company announced the decision on November 10. The authorization allows its use to remove bladder lesions in adults and obtain tissue samples, including bladder muscle, to help diagnose bladder cancer. It does not show that the system improves survival or prevents cancer from returning. The device must be operated by trained surgeons in an operating room.

The FDA had previously given the system Breakthrough Device Designation in September 2025, a step that allowed the company to receive additional regulatory guidance during development. Virtuoso plans a limited U.S. launch in 2027, beginning with major urology centers. It has not named the first hospitals, and pricing and insurance coverage have not been announced.

The company is also exploring possible uses for its miniature instruments in lung procedures, but those applications remain experimental and are not FDA-authorized. For now, the system is focused on bladder surgery.

For patients, the device could eventually offer another option for removing a bladder tumor and collecting tissue. But access is likely to be limited at first, and the early results need to be confirmed in larger studies. FDA authorization alone does not guarantee better outcomes for every patient.

Anyone discussing bladder tumor surgery with a urologist can ask whether en bloc resection is appropriate and how the surgeon plans to collect enough tissue to determine whether the cancer has reached the bladder muscle. Those details may help clarify the available options before surgery.

Facebook
Twitter
LinkedIn
Reddit
Telegram
WhatsApp

Related News